Table 2.
Baseline demographic and clinical characteristics of uterus-intact OS women with early menopause (<40 yrs), with or without prior or current HT use
| Early menopause, no HT (n=524) |
Early menopause, HT (n=2,017) |
p- value |
|
|---|---|---|---|
| Age group at screening, years | 0.01 | ||
| 50 – 59 | 124 (24%) | 528 (26%) | |
| 60 – 69 | 224 (43%) | 953 (47%) | |
| 70 – 79+ | 176 (34%) | 536 (27%) | |
| Mean (SD) (min, max) | 65.4 (7.5) (50 – 79) | 64.4 (7.3) (50 – 79) | |
| Time since menopause, years | 0.84 | ||
| 10 – 19 | 62 (12%) | 245 (12%) | |
| > 19 | 462 (88%) | 1772 (88%) | |
| Ethnicity | <.01 | ||
| White (not of Hispanic origin) | 346 (66%) | 1636 (81%) | |
| Black/African-American | 131 (25%) | 211 (10%) | |
| Hispanic/Latino | 31 (6%) | 87 (4%) | |
| American Indian/Alaskan Native | 2 (<1%) | 15 (1%) | |
| Asian/Pacific Islander | 6 (1%) | 40 (2%) | |
| Other | 8 (2%) | 20 (1%) | |
| Missing | 0 (<1%) | 8 (<1%) | |
| Body Mass Index (BMI), kg/m2 | <.01 | ||
| <25 | 158 (30%) | 742 (37%) | |
| 25 – <30 | 166 (32%) | 704 (35%) | |
| ≥ 30 | 196 (37%) | 549 (27%) | |
| Missing | 4 (1%) | 22 (1%) | |
| Mean (SD) (min, max) | 28.9 (6.5) (17.1 – 58.3) | 27.6 (5.6) (15.3 – 65.5) | |
| Physical Activity (METS/week) | <.01 | ||
| 0 – 3 | 196 (37%) | 574 (28%) | |
| >3 to <11.75 | 156 (30%) | 630 (31%) | |
| ≥ 11.75 | 171 (33%) | 789 (39%) | |
| Missing | 1 (<1%) | 24 (1%) | |
| # of falls in the previous 12 months | 0.46 | ||
| 0 | 356 (68%) | 1314 (65%) | |
| 1 | 101 (19%) | 380 (19%) | |
| 2 | 40 (8%) | 171 (8%) | |
| ≥ 3 | 24 (5%) | 124 (6%) | |
| Missing | 3 (1%) | 28 (1%) | |
| Smoking status | 0.03 | ||
| Never | 245 (47%) | 984 (49%) | |
| Past | 215 (41%) | 863 (43%) | |
| Current | 55 (10%) | 142 (7%) | |
| Missing | 9 (2%) | 28 (1%) | |
| ETOH use | <.01 | ||
| None | 105 (20%) | 248 (12%) | |
| Past use | 132 (25%) | 458 (23%) | |
| <1 drink/month | 68 (13%) | 240 (12%) | |
| <1 drink/week | 77 (15%) | 418 (21%) | |
| 1 to <7 drinks/week | 91 (17%) | 419 (21%) | |
| ≥7 drinks/week | 50 (10%) | 216 (11%) | |
| Missing | 1 (<1%) | 18 (1%) | |
| Diabetes ever at screening | <.01 | ||
| No | 457 (87%) | 1870 (93%) | |
| Yes | 67 (13%) | 142 (7%) | |
| Missing | 0 (<1%) | 5 (<1%) | |
| Currently have diabetes at screening | <.01 | ||
| No | 465 (89%) | 1900 (94%) | |
| Yes | 58 (11%) | 109 (5%) | |
| Missing | 1 (<1%) | 8 (<1%) | |
| Glucocorticosteroid taken orally and daily at screening | 0.63 | ||
| No | 516 (98%) | 1980 (98%) | |
| Yes | 8 (2%) | 37 (2%) | |
| Bisphosphonate use at screening | 0.69 | ||
| No | 508 (97%) | 1962 (97%) | |
| Yes | 16 (3%) | 55 (3%) | |
| Vitamin D intake (mean IU/day) | <.01 | ||
| < 200 | 262 (50%) | 717 (36%) | |
| 200 – <400 | 86 (16%) | 324 (16%) | |
| 400 – <600 | 113 (22%) | 527 (26%) | |
| ≥ 600 | 63 (12%) | 449 (22%) | |
| Calcium intake (mean mg/day) | <.01 | ||
| <800 | 272 (52%) | 696 (35%) | |
| 800 – <1200 | 109 (21%) | 464 (23%) | |
| ≥1200 | 143 (27%) | 857 (42%) | |